Clinical Trial Update: Phase 2 Study With PQR309 in Relapsed or Refractory Lymphoma Patients [Phase 2]

View source ↗

Summary

Phase 2 study of PQR309 in relapsed or refractory lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• PQR309

Snippet

Sponsor: PIQUR Therapeutics AG | Conditions: Lymphoma, Non-Hodgkin Lymphoma | Phase 2 | Status: COMPLETED